News from trovagene, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 20, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Provides Update on Its Urine-Based HPV Test

Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will...

Aug 12, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined...

Aug 07, 2014, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene, Inc. Announces Second Quarter 2014 Financial Results

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months...

Jul 30, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call

Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the...

Jul 01, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance

 Trovagene, Inc. (NASDAQ:  TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from...

Jun 30, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute

 Trovagene, Inc. (NASDAQ:  TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the...

Jun 16, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. (NASDAQ:  TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to...

Jun 02, 2014, 12:45 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Oncogene Mutation Signal in Urinary Cell Free DNA is Highly Correlated with Treatment Response

 Trovagene, Inc. (NASDAQ:  TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal...

May 28, 2014, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene to Present at Jefferies 2014 Global Healthcare Conference

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni...

May 28, 2014, 09:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene's Precision Cancer Monitoring Technology Referenced in Multi-Disciplinary Clinical Consensus Guidelines

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that the multi-disciplinary clinical consensus...

May 20, 2014, 09:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Announces Publication of Data from Clinical Validation Program Using Its Precision Cancer Monitoring Platform

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data published from ongoing clinical...

May 14, 2014, 17:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Announces Data Presentations, Published Abstracts at Annual Meeting of American Society of Clinical Oncology

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today announced that data from a study of its precision...

May 12, 2014, 16:01 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene, Inc. Announces First Quarter 2014 Financial Results

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months...

May 05, 2014, 16:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Schedules Release of First Quarter 2014 Financial Results and Investor Conference Call

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the...

Apr 08, 2014, 11:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Clinical Data Presented at AACR Demonstrate Ability of Trovagene's Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients' Response to Therapy

Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's...

Apr 01, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's...

Mar 26, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined...

Mar 19, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care

Trovagene, Inc. (NASDAQ:  TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into...

Mar 17, 2014, 16:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and...

Mar 17, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Releases Its First Oncogene Mutation Assay Using Next Generation Sequencing, Expands Its Non-Invasive Cancer Monitoring Platform

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed...